Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04ISS
|
||||
Former ID |
DIB002444
|
||||
Drug Name |
SAR-1118
|
||||
Synonyms |
Dual LFA-1/ICAM-1 inhibitors, Sunesis; Dual LFA-1/ICAM-1 inhibitors (inflammatory diseases), SARcode; Dual leukocytefunction-associated antigen-1/intracellular adhesion molecule-1 inhibitors (inflammatory diseases), SARcode
|
||||
Drug Type |
Small molecular drug
|
||||
Company |
Sunesis Pharmaceuticals Inc
|
||||
Formula |
C29H24Cl2N2O7S
|
||||
InChI |
InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
|
||||
InChIKey |
JFOZKMSJYSPYLN-QHCPKHFHSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Lymphocyte function-associated antigen 1 | Target Info | Inhibitor | [532142] | |
ICAM-1 | Target Info | Inhibitor | [532815] | ||
KEGG Pathway | Rap1 signaling pathway | ||||
Cell adhesion molecules (CAMs) | |||||
Natural killer cell mediated cytotoxicity | |||||
Leukocyte transendothelial migration | |||||
Regulation of actin cytoskeleton | |||||
Malaria | |||||
Staphylococcus aureus infection | |||||
HTLV-I infection | |||||
Epstein-Barr virus infection | |||||
Rheumatoid arthritis | |||||
Viral myocarditishsa04064:NF-kappa B signaling pathway | |||||
TNF signaling pathway | |||||
African trypanosomiasis | |||||
Influenza A | |||||
Viral myocarditis | |||||
Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
Cell surface interactions at the vascular wall | |||||
Integrin cell surface interactionsR-HSA-198933:Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
Integrin cell surface interactions | |||||
Interferon gamma signaling | |||||
WikiPathways | Focal Adhesion | ||||
Integrin-mediated Cell Adhesion | |||||
Integrin cell surface interactions | |||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
Cell surface interactions at the vascular wallWP619:Type II interferon signaling (IFNG) | |||||
IL1 and megakaryotyces in obesity | |||||
Human Complement System | |||||
Spinal Cord Injury | |||||
Interleukin-11 Signaling Pathway | |||||
RANKL/RANK Signaling Pathway | |||||
Folate Metabolism | |||||
Vitamin B12 Metabolism | |||||
Selenium Micronutrient Network | |||||
References | |||||
Ref 523596 | ClinicalTrials.gov (NCT01421498) Safety and Efficacy Study of SAR 1118 to Treat Dry Eye. U.S. National Institutes of Health. | ||||
Ref 542538 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7533). | ||||
Ref 532142 | Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. | ||||
Ref 532815 | Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.